All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
Formulary
Back
Contact us about this page
Chapter 1: Gastrointestinal
Toggle Parent Pages
Print this page
Inflammatory bowel disease guidance
Irritable bowel syndrome guidance
Management of constipation in adults
Management of constipation in children
Management of dyspepsia and gastro-oesophageal reflux disease
Paediatric reflux disease guidance
Infantile Colic guidance
1.1 Dyspepsia and gastro-oesophageal reflux disease
1.2 Antispasmodics and other drugs altering gut motility
1.3 Antisecretory drugs and mucosal protectants
1.4 Antimotility drugs
1.5 Chronic bowel disorders
1.6 Laxatives
1.7 Local preparations for anal and rectal disorders
1.8 Stoma care
1.9 Drugs affecting intestinal secretions
Page last updated:
14 September 2022
Contact us about this page
1.5.4 Glucagon-like peptide-2 receptors (GLP-2R)
First Line
Second Line
Specialist
Hospital Only
Teduglutide
- Powder and solvent for solution for injection vial 1.25mg, 5mg
Notes
- NICE TA804: Teduglutide (Revestive) is recommended, within its marketing authorisation, as an option for treating short bowel syndrome (SBS) in people 1 year and above (June 2022). People's condition should be stable following a period of intestinal adaptation after surgery before having teduglutide. Teduglutide is recommended only if the company provides it according to the commercial arrangement.
